QTTBNasdaqPharmaceutical PreparationsFiscal year ends December 31

Q32 Bio Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$7.79+0.27 (+3.59%)

Close on Oct 19, 2026

Market cap: $158.47M
P/E (TTM): 3.2
Dividend yield: –

Fundamental chart

Pick a measure to chart its full history

$53.74MFY2025, +39.1% a year since FY2018

Where these numbers come from

Parsed from the XBRL in Q32 Bio's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-166 reverse split on May 9, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is QTTB.

Operating margin39.9% · median -262.0%

Net margin62.9% · median -435.8%

Company	Revenue	Growth
VRDN	$71.13M	+23220.3%
NKTR	$55.23M	-43.9%
QTTB	$53.74M	–
CUE	$37.65M	+354.4%
ZBIO	–	–
EQ	–	–

Company

Next earnings (est.): Nov 12, 2026, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 24
Held by institutions: 74.6%
Auditor: Ernst & Young LLP
SEC CIK: 1661998

Advertisement
300 × 250